AC Immune (ACIU) Upgraded to “Hold” at BidaskClub

Share on StockTwits

AC Immune (NASDAQ:ACIU) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday, October 19th.

Other research analysts have also recently issued reports about the company. HC Wainwright set a $18.00 price objective on AC Immune and gave the company a “buy” rating in a report on Thursday, August 9th. ValuEngine raised AC Immune from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Finally, Zacks Investment Research lowered AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. AC Immune has an average rating of “Hold” and a consensus target price of $14.00.

Shares of AC Immune stock traded down $0.16 on Friday, hitting $8.73. 34,063 shares of the company were exchanged, compared to its average volume of 111,650. AC Immune has a 1-year low of $7.16 and a 1-year high of $17.40. The stock has a market cap of $580.91 million, a P/E ratio of -29.10 and a beta of 1.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.65 and a quick ratio of 9.65.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. AC Immune had a negative return on equity of 25.44% and a negative net margin of 133.00%. The firm had revenue of $2.03 million for the quarter, compared to analysts’ expectations of $1.92 million. As a group, research analysts expect that AC Immune will post -0.93 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in shares of AC Immune by 28.9% during the third quarter. FMR LLC now owns 5,209,673 shares of the company’s stock worth $41,678,000 after acquiring an additional 1,166,524 shares during the period. Janus Henderson Group PLC purchased a new position in AC Immune in the third quarter valued at $13,345,000. Artal Group S.A. increased its holdings in AC Immune by 25.0% in the third quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $6,000,000 after buying an additional 150,000 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in AC Immune in the third quarter valued at $626,000. Finally, JPMorgan Chase & Co. purchased a new position in AC Immune in the third quarter valued at $142,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

See Also: Fiduciary

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.